Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for seamless phase I-II trials in oncology

References

• Abramowitz, M., and I. A. Stegun. 1968. Handbook of mathematical functions with formulas, graphs, and mathematical tables, vol. 55. Washington, DC, USA: US Government printing office.
   Google Scholar
• Guo, W., S.-J. Wang, S. Yang, H. Lynn, and Y. Ji. 2017. A Bayesian interval dose-finding design addressingOckham’s razor: mTPI-2. Contemporary Clinical Trials 58:23–33. doi:10.1016/j.cct.2017.04.006.
   PubMed Web of Science ®Google Scholar
• Huang, X., S. Biswas, Y. Oki, J.-P. Issa, and D. A. Berry. 2007. A parallel phase I/II clinical trial design for combination therapies. Biometrics Bulletin 63 (2):429–436. doi:10.1111/j.1541-0420.2006.00685.x.
   Google Scholar
• Ji, Y., P. Liu, Y. Li, and B. Nebiyou Bekele. 2010. A modified toxicity probability interval method for dose-finding trials. Clinical Trials 7 (6):653–663. doi:10.1177/1740774510382799.
   PubMed Web of Science ®Google Scholar
• Lin, R., Y. Zhou, F. Yan, D. Li, and Y. Yuan. 2020. BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precision Oncology 4 (4):1393–1402. doi:10.1200/PO.20.00257.
   Google Scholar
• Liu, M., S.-J. Wang, and Y. Ji. 2020. The i3+3 design for phase I clinical trials. Journal of Biopharmaceutical Statistics 30 (2):294–304. doi:10.1080/10543406.2019.1636811.
   PubMed Web of Science ®Google Scholar
• Liu, S., and Y. Yuan. 2015. Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 (3):507–523. doi:10.1111/rssc.12089.
   Web of Science ®Google Scholar
• Meibohm, B., and H. Derendorf. 1997. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. International Journal of Clinical Pharmacology and Therapeutics 35 (10):401–413.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., M. Pepe, and L. Fisher. 1990. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics Bulletin 46 (1):33–48. doi:10.2307/2531628.
   Google Scholar
• Pan, H., F. Xie, P. Liu, J. Xia, and Y. Ji. 2014. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials 11 (1):49–59. doi:10.1177/1740774513500081.
   PubMed Web of Science ®Google Scholar
• Patterson, S., S. Francis, M. Ireson, D. Webber, and J. Whitehead. 1999. A novel Bayesian decision procedure for early-phase dose-finding studies. Journal of Biopharmaceutical Statistics 9 (4):583–597. doi:10.1081/BIP-100101197.
   PubMedGoogle Scholar
• Piantadosi, S., and G. Liu. 1996. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 15 (15):1605–1618. doi:10.1002/(SICI)1097-0258(19960815)15:15<1605:AID-SIM325>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Robertson, D. S., K. M. Lee, B. C. López-Kolkovska, and S. S. Villar. 2023. Response-adaptive randomization in clinical trials: From myths to practical considerations. Statistical Science: A Review Journal of the Institute of Mathematical Statistics 38 (2):185. doi:10.1214/22-STS865.
   PubMed Web of Science ®Google Scholar
• Shargel, L., B. Andrew, and S. Wu-Pong. 1999. Applied biopharmaceutics & pharmacokinetics, vol. 264. Stamford, Connecticut, USA: Appleton & Lange Stamford.
   Google Scholar
• Storer, B. E. 1989. Design and analysis of phase I clinical trials. Biometrics Bulletin 45 (3):925–937. doi:10.2307/2531693.
   Google Scholar
• Su, X., Y. Li, P. Müller, C.-W. Hsu, H. Pan, and K.-A. Do. 2022. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling. Pharmaceutical Statistics 21 (6):1149–1166. doi:10.1002/pst.2249.
   PubMed Web of Science ®Google Scholar
• Tabrizi, M. A., C.-M. L. Tseng, and L. K. Roskos. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today 11 (1–2):81–88. doi:10.1016/S1359-6446(05)03638-X.
   PubMed Web of Science ®Google Scholar
• Thall, P. F., and J. K. Wathen. 2007. Practical bayesian adaptive randomisation in clinical trials. European Journal of Cancer 43 (5):859–866. doi:10.1016/j.ejca.2007.01.006.
   PubMed Web of Science ®Google Scholar
• Ting, N. 2006. Dose finding in drug development. Berlin, German: Springer Science & Business Media.
   Google Scholar
• Ursino, M., S. Zohar, F. Lentz, C. Alberti, T. Friede, N. Stallard, and E. Comets. 2017. Dose-finding methods for phase I clinical trials using pharmacokinetics in small populations. Biometrical Journal 59 (4):804–825. doi:10.1002/bimj.201600084.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 2023. Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases.
   Google Scholar
• Whitehead, J., S. Patterson, D. Webber, S. Francis, and Y. Zhou. 2001. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2 (1):47–61. doi:10.1093/biostatistics/2.1.47.
   PubMedGoogle Scholar
• Whitehead, J., Y. Zhou, L. Hampson, E. Ledent, and A. Pereira. 2007. A Bayesian approach for dose-escalation in a phase I clinical trial incorporating pharmacodynamic endpoints. Journal of Biopharmaceutical Statistics 17 (6):1117–1129. doi:10.1080/10543400701645165.
   PubMed Web of Science ®Google Scholar
• Yuan, Z., R. Chappell, and H. Bailey. 2007. The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach. Biometrics Bulletin 63 (1):173–179. doi:10.1111/j.1541-0420.2006.00666.x.
   Google Scholar